Document is current
Any future updates will be listed below
-
Authors
Vandekerckhove, Linos https://orcid.org/0000-0002-8600-1631
Fox, Julie https://orcid.org/0000-0002-0583-8019
Mora-Peris, Borja https://orcid.org/0000-0002-4719-6827
Navarro, Jordi https://orcid.org/0000-0002-7187-0367
Allard, Sabine D.
Uriel, Alison J.
Moreno Guillén, Santiago
Boffito, Marta
Post, Frank A. https://orcid.org/0000-0002-2844-1612
Estrada, Vicente
Mothe, Beatriz https://orcid.org/0000-0001-9975-407X
Delporte, Mareva https://orcid.org/0000-0002-4423-3012
Benlahrech, Adel https://orcid.org/0009-0003-3174-482X
Rahman, Haseeb
Clubley, James https://orcid.org/0009-0004-1823-4136
Treveil, Agatha https://orcid.org/0000-0002-5600-8189
Chamberlain, Jonathan
Harrison, Rory
Hock, Miriam https://orcid.org/0009-0007-4353-3738
Yuan, Yuan
Wustner, Jason
Moureau, Sylvie
Whale, Andrew D. https://orcid.org/0000-0002-9931-3706
Wallace, Zoë
Singh, Praveen K.
Titanji, Kehmia
Dorrell, Lucy
Fidler, Sarah https://orcid.org/0000-0003-1676-7583
-
Funding
Funding for this research was provided by:
L.V. receives research grants from J&J, ViiV Healthcare and Gilead Sciences
- License Information
-
More Information
Article History
Received: 13 December 2024
Accepted: 13 January 2026
First Online: 31 January 2026
Competing interests
: L.V. receives research grants from J&J, ViiV Healthcare and Gilead Sciences. J.N. has received fees for educational activities and/or consultancies and/or financial support for attending conferences from AbbVie, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme and ViiV Healthcare; S.D.A has received research grants and/or consulting fees from Gilead Sciences, GSK, MSD and ViiV Healthcare. A.J.U. has received financial support for attending a conference from Gilead Sciences. M.B. has received research grants and/or consulting fees from ViiV, Gilead, MSD, GSK, Novavax, Valneva, Cipla, Mylan, Janssen, and Roche. V.E. has received fees for educational activities and/or consultancies and/or financial support for attending conferences from Gilead Sciences, Janssen-Cilag, Merck Sharp and Dohme and ViiV Healthcare. B.M. has received consultancy fees from AELIX Therapeutics SL and AbbVie and speaker fees from Gilead, Janssen and ViiV Healthcare. M.D. was supported by the NIH MDC grant RID-HIV: UM1AI164561 and PO1 AI178376. A.B., H.R., A.T., J.C., R.H., M.H., Y.Y., J.W., S.M., A.D.W., Z.W., P.K.S., K.T., and L.D. were/are employees of Immunocore Ltd. The remaining authors declare no competing interests.
